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Abstract 
Autologous hematopoietic cell transplantation (HCT) followed by nonmyeloablative allogeneic 
HCT (auto/alloHCT) provides cytoreduction and graft-versus-myeloma effects. We report on long-
term outcomes of 102 patients with multiple myeloma who received auto/alloHCT with a median 
follow-up of 6.3 years. Treatment consisted of high-dose melphalan and autograft followed by 2-Gy 
total body irradiation, with or without fludarabine, and alloHCT from human leukocyte antigen-
identical siblings. Postgrafting immunosuppressive agent was cyclosporine or tacrolimus and 
mycophenolate mofetil. Forty-two percent of patients developed grade 2 to 4 acute graft-versus-host 
disease (GVHD) and 74% extensive chronic GVHD. Five-year nonrelapse mortality after 
allografting was 18%, 95% related to GVHD or infections. Among 95 patients with detectable 
disease, 59 achieved complete remissions. Median time to progression was 5 years. Median overall 
survival (OS) was not reached. Median progression-free survival (PFS) was 3 years. Five-year OS 
and PFS were 64% and 36%, respectively. Seventy-three patients receiving autoHCT within 10 
months from treatment initiation had 5-year OS of 69% and PFS of 37%. In multivariate analysis, 
β-2-microglobulin of more than 3.5 μg/mL at diagnosis and auto/alloHCT more than 10 months 
after treatment initiation correlated with shorter OS (P = .03 and P = .02) and PFS (P = .04 and P = 
.03), whereas Karnofsky scores less than 90% at allotransplantation correlated with shorter PFS 
only (P = .005). Long-term disease control and GVHD remain key issues.  
   
Introduction 
The optimal therapy for advanced-stage multiple myeloma (MM) remains poorly defined. Long-
term remissions and possible cures have been described in patients who received allogeneic 
hematopoietic cell transplantation (HCT) after conventional high-dose conditioning regimens. In 
this setting, the addition of a graft-versus-myeloma (GVM) effect of donor T-cells may provide 
long-term disease control.
1–4
 Unfortunately, conventional allogeneic HCT has been associated with 
high nonrelapse mortality (NRM) and remains an option only for few selected patients.
5–8
 
Reduced-intensity conditioning (RIC) regimens as preparation for allogeneic HCT have been 
associated with lower NRM while maintaining GVM effects. The European Group for Blood and 
Marrow Transplantation reported a comparison between 320 RIC and 196 myeloablative allogeneic 
HCT performed in 103 centers between 1998 and 2002. The 2 patient groups were significantly 
different. Patients treated with RIC were older (median age, 51 vs 45 years; P < .001), more often 
had progressive disease (28% vs 21%; P = .001), and were more likely to be treated with one or 
more prior autologous HCT (76% vs 11%; P < .001). This retrospective comparison confirmed that 
conventional allogeneic HCT was significantly associated with higher NRM compared with RIC 
(hazard ratio [HR], 1.87; confidence interval [CI] 95%, 1.2-2.8; P = .003). However, conventional 
allogeneic HCT was associated with a significantly lower relapse rate compared with RIC (HR, 
0.51; CI 95%, 0.35-0.73; P < .001). T-cell depletion and the use of anti-CD52 antibody to control 
graft-versus-host disease (GVHD) were related to a higher relapse risk after RIC (HR, 2.3; P = .001 
and HR 1.6; P = .03, respectively), probably because of inhibition of GVM effects.
9
 
The use of RIC allogeneic HCT immediately after autologous HCT (auto/alloHCT) provides 
temporal separation between tumor reduction by high-dose chemotherapy and the GVM effect. Two 
preliminary studies showed NRM of 15% and 26% at 1 year after allografting, and high complete 
remission rates of 57% and 73%, respectively.
10,11
 These initial findings were both limited by small 
numbers of patients analyzed (52 and 17, respectively) and short follow-ups (median 18 and 13 
months, respectively). However, the approach was safe and feasible for elderly patients and those 
with comorbidities who would otherwise have been excluded from conventional allogeneic 
transplantation protocols.  
We previously published our experience on the use of auto/alloHCT for advanced stage MM in 52 
patients with a median follow-up of 1.5 years after allografting.
10
 Here, we update and extend the 
study to include 105 patients enrolled in multicenter allogeneic transplantation protocols designed 
and coordinated by the Fred Hutchinson Cancer Research Center (FHCRC) with a median follow-
up of 6.3 years after allografting.  
   
Methods 
Patients 
Patient inclusion criteria for this analysis were (1) stage II or III MM at diagnosis or thereafter; (2) 
available human leukocyte antigen (HLA)–identical sibling donor; (3) programmed sequential 
treatment with conventional autologous HCT followed by nonmyeloablative auto/alloHCT; and (4) 
no prior autologous HCT.  
One hundred five patients with MM fulfilling those criteria were sequentially enrolled at 10 centers 
on 4 FHCRC-coordinated multi-institutional protocols from August 1998 to August 2005. Patients 
proceeded to allogeneic HCT 40 to 180 days after autografting or whenever the following 
benchmarks were achieved: resolved mucositis with no need for intravenous hydration, renal and 
hepatic function returned to entry criteria, no need for intravenous antibiotics, and cytomegalovirus 
(CMV) antigen negative.  
Clinical characteristics of the patients are shown in Table 1, and disease status at autografting is 
shown in Table 2. Twenty-one patients (20%) received more than one induction therapy line for 
refractory (n = 7) or relapsed disease after previous response (n = 14).  
  
 
 
 Inclusion criteria for allotransplantation were serum bilirubin less than twice normal, left ventricular 
ejection fraction more than 40%, creatinine clearance more than 40 mL/min, and Karnofsky 
performance status more than 60%. Written informed consent was obtained from all patients and 
donors in accordance with the Declaration of Helsinki on protocols approved by the institutional 
review boards of all participating institutions.  
We retrospectively applied eligibility criteria for the ongoing Blood and Marrow Transplant 
Clinical Trial Network (BMT-CTN 0102) study in which double autologous (auto/auto) HCT is 
compared with auto/allo HCT. In our cohort, 76 patients fulfilled those criteria, having received 
autologous HCT within 10 months after treatment initiation, and we separately analyzed the 
outcome of this subgroup. Moreover, we evaluated the differences among these patients and the 
remaining 29 who had auto/auto HCT initiated more than 10 months after treatment initiation. The 
latter received more previous chemotherapy cycles (median 7 vs 4; P = .001) and were more often 
reinduced after failure of previous therapy (41% vs 12%; P = .001). There were no other significant 
differences in characteristics and disease status at diagnosis and at allografting among the 2 
subgroups (data not shown).  
Definition and assessment of prognostic factors at allografting 
Serum albumin and β-2-microglobulin at diagnosis were available in 70 patients and used to 
calculate the International Staging Score (ISS).
12
 
Comorbidities were assessed at allografting and described using an HCT-specific comorbidity index 
(HCT-CI).
13
 Performance status at allografting was described with the Karnofsky scale.
14
 
Cytogenetic analyses were not planned at diagnosis or before allografting by protocol and were not 
routinely performed in all the participating centers during the years of enrollment of these patients. 
Nonetheless, we retrospectively collected data on conventional cytogenetic metaphase studies at 
autografting in 66 patients. Data on chromosome 13 deletion studied with fluorescence in situ 
hybridization (FISH) analysis for 13q14 were available in 18 patients at autografting (Table 1). 
Cytogenetic abnormalities evaluated at autografting with conventional karyotype were included as a 
covariate in the statistical analysis (Table 5).  
Treatment 
Autologous HCT. 
Autologous granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood 
mononuclear cells (G-PBMC) were harvested by leukapheresis after treatment with 
cyclophosphamide 3 to 4 g/m
2
 (day +1) and G-CSF 10 μg/kg subcutaneously (from day +3 through 
collection); 38 patients received additional paclitaxel (250 mg/m
2
 per day, day +2), and 25 received 
additional etoposide (200 mg/m
2
 per day; days +1, +2, +3) and dexamethasone (10 mg/day orally; 
days +1, +2, +3, +4). Two patients received G-CSF alone.  
High-dose chemotherapy consisted of melphalan, 200 mg/m
2
 infused intravenously, at least 28 days 
after G-PBMC collection. Two patients received melphalan, 140 mg/m
2
, as a result of renal failure, 
and one patient with plasmablastic MM received 1,3-bis(2-chloroethyl)-1-nitroso-urea (BCNU) 
(300 mg/m
2
 [day −7], etoposide (200 mg/m2 per day [days −6, −5, −4, −3]), cytarabine (200 mg/m2 
per day [days −6, −5, −4, −3]), and melphalan (140 mg/m2 [day −2]; BEAM regimen). No treatment 
for MM was given between autologous and allogeneic HCT.  
Allogeneic HCT. 
After recovery from autologous HCT, 102 patients proceeded to allotransplantation. Donors were 
HLA-identical siblings and received G-CSF 16 μg/kg per day from days −4 to 0 and leukaphereses 
on days −1 and 0. Donor G-PBMC harvested on day −1 were held overnight and infused with the 
day 0 collection.  
Nonmyeloablative conditioning consisted in all patients of 2 Gy total body irradiation (TBI) at 7 
cGy/min by linear accelerator or cobalt on day 0. Twenty-seven patients received additional 
fludarabine (30 mg/m
2) on days −4, −3, and −2.  
Donor G-PBMCs were infused after TBI. Postgrafting immunosuppression included mycophenolate 
mofetil (MMF; 15 mg/kg orally twice a day from the evening of day 0 until day +27) and 
cyclosporine (CSP; 5.0-6.25 mg/kg orally twice a day from day −3 to day +56 or +80 and then 
tapered) or tacrolimus (0.06 mg/kg orally twice a day from day −3 to day +56, and then 
tapered).
10,15
 Patients received standard supportive care and antimicrobial prophylaxis while CMV 
reactivation was monitored and treated with ganciclovir.  
Donor chimerism was assessed 28, 56, 180, and 360 days after allogeneic HCT on peripheral blood 
T cells, granulocytes, and unfractionated marrow using FISH analysis in sex-mismatched pairs and 
polymerase chain reaction analyses of polymorphic microsatellite regions in sex-matched pairs.
16
 
Disease responses 
Disease responses were defined according to the International Uniform Response Criteria for 
multiple myeloma.
17
 Complete remission (CR) required absence of monoclonal protein in serum 
and urine by protein electrophoresis and by immunofixation, less than 5% plasma cells in marrow 
aspirates, absence of clonal disease by flow cytometry, and no increase in osteolytic lesions. Very 
good partial remission (VGPR) was defined as detection of serum monoclonal protein and/or 
Bence-Jones proteinuria by immunofixation but not by electrophoresis or at least 90% reduction in 
Bence-Jones proteinuria with excretion less than 100 mg/24 hours, and no increase in size or 
number of osteolytic lesions. Partial remission (PR) was defined as more than 50% reduction in the 
levels of serum monoclonal protein, more than 90% reduction in Bence-Jones proteinuria with 
excretion less than 200 mg/24 hours, and no increase in size or number of osteolytic lesions. 
Patients with less than a PR after induction chemotherapy or autografting were considered 
refractory, whereas the disease was considered stable if no response meeting the criteria of CR, 
VGPR, or PR was observed after allografting. Progressive disease was considered an increase in 
serum monoclonal proteins or urine light chains of at least 25% in patients with refractory or stable 
disease, whereas relapse was considered as the reappearance of bone marrow infiltration; serum 
monoclonal immunoglobulin or urine light chains or new bone lesions in patients in previous CR; 
or a 25% increase in any disease marker for patients in prior PR. Patients were evaluated for disease 
once before autologous conditioning and once before nonmyeloablative conditioning to estimate 
baseline levels of disease activity before each transplantation. Disease responses were assessed 56, 
84, and 180 days after allotransplantation and thereafter at 6-month intervals or according to clinical 
status.  
Toxicities and GVHD evaluation 
Regimen-related toxicities during the first 100 days after allotransplantation were evaluated 
according to National Cancer Institute (NCI) Common Terminology Criteria version 2 (CTC v2.0) 
grading system (http://ctep.cancer.gov/reporting/ctc.html). Grading and treatment of acute and 
chronic GVHD were performed according to established criteria.
18
 The date of discontinuation of 
all immunosuppressive therapy for surviving patients was obtained by chart review and contact with 
participating centers.  
End points 
Primary end points of the study were evaluation of overall and progression-free survivals after 
nonmyeloablative allotransplantation. Secondary end points were assessment of disease responses, 
evaluation of NRM, and incidence of acute and chronic GVHD.  
Statistical methods 
Overall and progression-free survival were estimated by the Kaplan-Meier method. Cumulative 
incidences of relapse, NRM, and chronic GVHD were estimated by methods described previously.
19
 
Prevalence of chronic GVHD was estimated according to the method of Pepe et al.
20
 Cox regression 
analysis was used for univariate and multivariate analysis of risk factors for mortality, relapse, and 
NRM, with relapse and NRM considered competing risks. Acute and chronic GVHD were 
considered as time-dependent covariates in such analyses.  
   
Results 
Autologous HCT 
Toxicities and infections. 
Most patients experienced mucositis, nausea and vomiting, and diarrhea and required a median of 7 
(range, 0-38) days' hospitalization after high-dose melphalan. The median numbers of days of 
neutrophil counts less than 500/μL and platelet counts less than 2 × 104/μL were 8 (range, 0-21) and 
3 (range, 0-38), respectively. Patients received a median of 1 transfusion (range, 0-21) of red blood 
cells (RBCs) and 1 transfusion (range, 0-130) of platelets (PTLs). Fifty-seven documented 
infections were reported: 35 bacterial, 13 viral (including 6 CMV reactivation and 1 CMV 
infection), and 9 fungal. Two patients, both with rapidly progressive myeloma, died after 
developing CMV pneumonitis and disseminated fungal infection, 31 and 163 days after autologous 
HCT, respectively.  
Allogeneic HCT 
The median time between autologous and allogeneic HCT was 69 (range, 40-281) days. Four 
patients received their planned allotransplants more than 180 days after autologous HCT to fulfill 
the recovery criteria. Three patients who underwent autologous HCT within 10 months of initiation 
of treatment for MM did not receive their allotransplants because of rapidly progressive disease and 
death from infections 1 and 4 months after high-dose melphalan (n = 2) and for insurance reasons (n 
= 1). This latter patient later received his allotransplantation off protocol.  
Engraftment. 
All 102 allografted patients had sustained engraftment. On day +28, medians of 90%, 95%, and 
95% of peripheral blood T cells, granulocytes, and nucleated marrow cells, respectively, were of 
donor origin. This increased to medians of 96% to 100% on day +84. One patient with 25% donor 
T-cell chimerism on day +84 received, on day +117, pentostatin (1 mg/m
2
), followed by donor 
leukocyte infusion (DLI) of 1 × 10
7
 CD3 cells/kg, on day +119. He subsequently evolved to 70% T-
cell chimerism, 120 days after DLI.  
Regimen-related toxicities, GVHD, and infections. 
The nonmyeloablative low-dose TBI was generally well tolerated. Fifteen percent of patients 
experienced neutropenia and 8% thrombocytopenia with median periods of neutrophil counts less 
than 500/μL and platelet counts less than 2 × 104/μL of 5 (range, 2-19) days and 1 (range, 1-3) days, 
respectively. Eight percent of patients required transfusions for a median of 2 (range, 1-39) RBCs 
and 3 (range, 2-32) PTLs, respectively. During the first 100 days after transplantation, 31% of 
patients had transient increases in serum creatinine levels (22% grade 2 and 9% grade 3 toxicity), 
20% had transient hyperbilirubinemia and increases in serum transaminases not related to GVHD 
(10% grade 2 and 10% grade 3), 12% had hypertension and sinus tachycardia (3% grade 2 and 9% 
grade 3), 1% had sinus bradycardia (grade 4), 12% had nausea and vomiting (6% grade 2 and 6% 
grade 3), 2% had anorexia requiring parenteral nutrition (grade 4), 8% had neurologic changes such 
as tremors and confusion (4% grade 2 and 4% grade 3) and hallucination and seizures, and 1% had 
stupor and failure to thrive (grade 4). Most of these adverse events were transitory and probably due 
to CSP or tacrolimus. During the first 100 days after allografting, 81% of patients were treated 
entirely in the outpatient setting, whereas 19% required hospitalization for a median of 5 (range, 2-
42) days.  
Forty-three patients (42%) developed grades 2 to 4 acute GVHD at a median of 42 (range, 8-107) 
days after allotransplantation. This was grade 2 in 34 patients, grade 3 in 4 patients, and grade 4 in 5 
patients (Figure 1A). The sites involved in GVHD were skin, gut, and liver (n = 12), skin and gut (n 
= 9), skin and liver (n = 5), and skin only (n = 4). In most patients, GVHD responded either to 
resumption of CSP, MMF, or treatment with methylprednisolone (at 1-2 mg/kg per day with 
subsequent taper).  
 
 
 
  
Seventy-four patients (74%) developed chronic extensive GVHD at a median of 167 (range, 90-
830) days after transplantation. The estimated percentage of patients remaining on 
immunosuppressive therapy at 1, 2, and 5 years after transplantation was 49%, 44%, and 33%, 
respectively (Figure 1B). All documented infections and viral reactivations after allografting are 
described in Table S1 (available on the Blood website; see the Supplemental Materials link at the 
top of the online article).  
Disease response. 
Disease responses after autologous and allogeneic HCT are summarized in Table 2, and patient 
disease status at each phase of treatment is shown in Table 3. Among 83 patients who had 
detectable disease before allografting, 47 (57%) obtained CR at a median of 208 (range, 28-773) 
days after allografting. Achieving CR was not significantly associated with chronic GVHD (HR, 
0.60; CI, 95% 0.3-1.3; P = .18).  
 
  
 
 
 
 
  
Kaplan-Maier estimates of OS and PFS in patients receiving tandem auto/allo HCT. (A) OS 
(blue lines) in 102 patients who completed the tandem auto/alloHCT (solid line) and in the 
subgroup of 73 patients who received autoHCT within 10 months from treatment beginning (dotted 
line) and PFS (red lines) in 102 patients who completed the tandem auto/alloHCT (solid line) and in 
the subgroup of 73 patients who received autoHCT within 10 months from treatment beginning 
(dotted line). (B) Cumulative incidence of disease progression or relapse (blue lines) in 102 patients 
who completed the tandem auto/alloHCT (solid line) and in the subgroup of 73 patients who 
received autoHCT within 10 months from treatment beginning (dotted line) and NRM (red lines) in 
102 patients who completed the tandem auto/alloHCT (solid line) and in the subgroup of 73 patients 
who received autoHCT within 10 months from treatment beginning (dotted line). (C-E) Kaplan 
Maier estimates of PFS. (C) Disease status at autoHCT: CR/VGPR (blue line, n = 26), PR (red line, 
n = 50), < PR (green line, n = 26). (D) Disease status at alloHCT: CR/VGPR (blue line, n = 43), PR 
(red line, n = 41), < PR (green line, n = 18). (E) Karnofsky performance status at alloHCT: more 
than 90% (red line, n = 66), less than 90% (blue line, n = 33). (F) Overall survival from disease 
relapse or progression in 51 patients who completed the tandem auto/alloHCT (solid line) and in the 
subgroup of 36 patients who received autoHCT within 10 months from treatment beginning (dotted 
line).  
 
Relapse. 
Fifty percent of patients who completed the treatment (51/102) had disease progression or relapse 
after allografting. The median time to relapse after allotransplantation was 5 years (Figure 2B). In 
particular, 47% of patients in CR (31/66), 54% of patients in VGPR (6/11), and 53% of patients in 
PR (10/19) eventually relapsed.  
 
 
β-2-Microglobulin level more than 3.5 μg/mL at diagnosis, Karnofsky performance status (KPS) 
less than 90% at allografting, and receiving autologous HCT more than 10 months after treatment 
initiation were risk factors for disease relapse after allografting by univariate and by multivariate 
analysis. Achieving less than PR at allografting was significantly related to relapse by univariate 
analysis but not multivariate analysis (Tables 5 and 6).  
Cytogenetic abnormalities or more than one course of induction therapy did not significantly affect 
relapse or progression after allografting by univariate analysis (Table 5). In the subgroup of 73 
patients who received their autologous HCT within 10 months from treatment initiation, median 
time to relapse after allotransplant was 5.3 years (Figure 2B).  
NRM. 
NRM was 1% at day +100 and 11%, 14%, and 18% at 1, 2, and 5 years after allografting, 
respectively (Figure 2B). GVHD and infections were responsible for 18 of 19 nonrelapse-related 
deaths. Acute grade 2 to 4 GVHD was significantly associated with NRM by univariate and 
multivariate analyses but not chronic extensive GVHD (Tables 5 and 6). However, chronic 
extensive GVHD and infectious complications accounted for 10 deaths, 3 of which occurred more 
than 3 years after allografting in patients who had achieved disease remission. Comorbidities (HCT-
CI ≥ 2), poor performance status (KPS < 90%) at allotransplantation, and age more than 60 years at 
allografting were not associated with higher risk of NRM (Table 5).  
Overall and progression-free survivals. 
After a median follow-up of 6.3 years after allografting (range 2-9), 60 of 102 (59%) patients 
survived and 33 of 102 (32%) are in remission. The causes of death for the 39 patients who 
completed the treatment are described in Table 4. Median overall survival (OS) has not been 
reached, whereas median progression-free survival (PFS) was 3 years. Five-year estimated OS and 
PFS were 64% and 36%, respectively (Figure 2A).  
 
 
 
 
By univariate analysis, mortality was significantly associated with β-2-microglobulin levels greater 
than 3.5 μg/mL at diagnosis, KPS less than 90% at allografting, achieving less than PR at 
allografting, auto/alloHCT more than 10 months after treatment initiation, and more than one 
induction regimen before auto/alloHCT (Table 5). By multivariate analysis, only β-2-microglobulin 
levels greater than 3.5 μg/mL at diagnosis and auto/alloHCT more than 10 months after treatment 
initiation were risk factors for mortality; other factors did not reach statistical significance (Table 
6).  
By univariate analysis, shorter PFS was significantly related to β-2-microglobulin levels greater 
than 3.5 μg/mL at diagnosis, achieving less than PR at allografting, auto/alloHCT more than 10 
months after treatment initiation, KPS less than 90% at allografting, and acute grade 2 to 4 GVHD 
(Table 5; Figure 2E). By multivariate analysis, β-2-microglobulin levels greater than 3.5 μg/mL at 
diagnosis, auto/alloHCT more than 10 months after treatment initiation, and KPS less than 90% at 
allografting maintained significant associations with shorter PFS (Table 6).  
In 83 patients who achieved CR after allografting, the achievement of CR, evaluated as a time-
dependent covariate, was associated with lower risk of overall and progression related mortality 
(HR, 0.17; CI 95% 0.1-0.4; P < .001 and HR, 0.50; CI, 95% 0.3-0.9; P = .02, respectively). In the 
subgroup of 73 patients who received their auto/alloHCT within 10 months from treatment 
initiation, median OS was not reached, whereas median PFS was 3.9 years. Five-year estimated OS 
and PFS were 69% and 37%, respectively (Figure 2A).  
Salvage therapy and survival after disease progression or relapse. 
Data on salvage therapy were available for 45 of 51 patients who had disease progression or relapse 
after allotransplantation. Treatment was initiated a median of 2 (range, 0.2-6.6) years after 
allografting. Treatments included thalidomide (n = 12), bortezomib (n = 10), bortezomib and 
thalidomide (n = 3), and conventional chemotherapy (n = 11). Nine patients received donor 
lymphocyte infusion (DLI) after a median of 41 (range, 3-81) months after allografting. Four had 
additional chemotherapy before DLI. After DLI, transient responses were observed in 2 patients 
who received additional chemotherapy, but all patients eventually developed progressive disease.  
After a median follow-up of 2.7 (range, 0.5-5.8) years from the time of relapse/progression, the 
median duration of survival after relapse was 3.7 years (Figure 2F). Patients with chronic GVHD 
documented before relapse tended to have a lower mortality rate after relapse (HR, 0.47; CI 95% 
0.2-1.1; P = .10). In the subgroup of 73 patients who received their auto/alloHCT within 10 months 
from treatment initiation, median overall survival after relapse was not reached and 5-year 
estimated survival after relapse was 57% (Figure 2F).  
   
Discussion 
Consolidation with 1 or 2 cycles of high-dose chemotherapy and autologous HCT has been 
considered optimal treatment for advanced stage MM for patients younger than 65 years of age. 
However, despite the superiority of autologous HCT in some but not all trials compared with 
conventional chemotherapy, this approach is not curative and most patients eventually relapse.
8,21–23
 
Up-front treatment with single versus double autologous HCT has been compared in 5 randomized 
studies.
24–28
 The largest trial, the IFM 94 study, consisting of 399 patients with a median follow-up 
of 6.2 years from randomization, showed a significant benefit of double autologous HCT compared 
with single autologous HCT. Median PFS and OS were 2.5 and 4.8 years, respectively, for double 
autologous HCT versus 2.1 and 4 years, respectively, for single autologous HCT.
25
 However, 
patients who had CR or very good PR after the first autologous HCT had no improvements in 
outcomes after a second autologous HCT, suggesting that additional high-dose melphalan does not 
eliminate the malignant clone and different approaches are needed.
25
 
Tandem autologous HCT with new agents such as thalidomide and bortezomib as induction, 
consolidation, and maintenance therapy has been used by the Arkansas group protocols. Barlogie 
and coworkers
29
 reported 5-year estimate OS and event-free survival (EFS) of 66% and 51%, 
respectively, in the Total Therapy 2 trial, and the results of the Total Therapy 3 trial, incorporating 
bortezomib in up-front therapy, were also encouraging: patients maintained sustained CRs.
30
 
Nonmyeloablative allotransplantation after autologous HCT (tandem auto/alloHCT) as 
consolidation of initial therapy may provide additional graft-versus-myeloma activity. Tandem 
auto/alloHCT has been compared with double autologous HCT in nonrandomized trials by 3 
groups, and prospective trials are ongoing.
31–33
 Garban and colleagues
31
 reported high-risk patients 
with elevated β-2-microglobulin levels and chromosome 13 deletion, as determined by FISH 
analysis. The allogeneic HCT conditioning regimen consisted of busulfan, fludarabine, and 
antithymocyte globulin. In this study, similar median PFS durations were observed in the 
auto/alloHCT group compared with the double autologous HCT group (2.6 vs 2.9 years; P = .35), 
and longer median OS durations were seen in the double autologous HCT group (2.9 vs 3.9 years; P 
= .07). The study by Bruno et al
32
 compared double autologous HCT versus tandem auto/alloHCT 
in MM, with the treatment assignment based on the availability of HLA-identical sibling donors. 
The conditioning regimen for allogeneic HCT was with 2-Gy TBI.
10,15
 In this study, a significant 
advantage was observed for the tandem auto/alloHCT group (median OS, not reached vs 4.8 years 
[P = .03] and median PFS, 3.6 vs 2.7 years [P = .07], respectively). Finally, a small study by 
Rosiñol et al
33
 compared tandem autologous HCT with autografting followed by RIC and 
allogeneic transplantation. In this study, patients with MM failing to achieve at least near-complete 
remission after a first autologous HCT received either a second autologous HCT or a RIC 
allogeneic HCT based on the availability of a HLA-identical sibling donor. Allogeneic HCT 
conditioning was with fludarabine and melphalan. They observed no statistical difference in PFS 
and OS between double autologous HCT and auto/alloHCT (median, 1.9 vs 1.6 years [P = .4] and 
median, 4.8 years vs not reached [P = .9]). Nonetheless, they reported a trend for a longer time to 
relapse after RIC allogeneic HCT than after second autologous HCT (median, 2.6 years vs not 
reached; P = .08).  
Here, we report on the largest series of patients with MM treated with auto/allo HCT with the 
longest follow-up published to date. The overall results were encouraging, with a median OS not 
reached and estimated OS at 5 years of 64%. Estimated PFS at 5 years was 36%. In particular, the 
subgroup of patients treated within 10 months from initiation of therapy had 5-year estimated OS 
and PFS of 69% and 37%, respectively.  
Attal et al reported in the IFM 94 study 5-year estimated OS values of 40% and 47% and 5-year 
estimated PFS values of 18% and 26% in the single and double autologous HCT groups, 
respectively.
25
 Comparison of these results is problematic, because we analyzed patients not 
uniformly treated at diagnosis and we used the day of allotransplantation for calculating overall and 
progression-free survivals, whereas Attal et al calculated survivals on an intention-to-treat basis 
from the day of randomization.  
We observed that, after auto/alloHCT, patients seemed to have a continuous risk of relapse. This 
may be different from the possible plateau observed with high-dose allogeneic HCT in younger 
patients.
5–8
 
Performance score at allografting was a major risk factor for relapse. This might be because MM, 
with associated osteolytic lesions, anemia, and renal impairment, had profound effects on patient 
well-being and levels of activity. Thus, Karnofsky scores might have reflected disease activity. 
Other studies have reported on the impact of performance status on OS
34–37
 and on PFS
38,39
 in 
patients with MM.  
In this series, cytogenetic studies were not performed at specific time points and with uniform 
methods. Within this limitation, the data did not show an effect of cytogenetics on relapse risk, 
supporting the notion that allogeneic transplantation might overcome bad prognostic genetic 
features of the MM clone. A recent study on the impact of specific cytogenetic abnormalities, 
evaluated with FISH, on survival after allogeneic transplantation in MM, showed that del(17p13) 
was the only studied cytogenetic feature with a significant negative impact on PFS, whereas other 
abnormalities, such as translocation t(4;14), might have been overcome by the allotransplant.
40
 
Ongoing studies, such as the Blood and Marrow Transplant Clinical Trial Network (BMT-CTN 
0102) prospective study comparing autologous-autologous with autologous-allogeneic, with 
planned FISH and conventional cytogenetics analysis at diagnosis and at allografting, will clarify 
the role of these cellular features in the allotransplantation setting and potentially give key 
indications for risk-adapted strategies.  
In contrast to what was reported for a larger group of patients with various diseases and donor type 
given nonmyeloablative conditioning allografting,
41
 in our series, poor performance status and 
presence of comorbidities were not related to an increased risk of NRM. In addition, being older 
than 60 years of age at allografting was not related to an increased risk of NRM, confirming the 
safety of the nonmyeloablative conditioning.  
GVHD was the main cause of NRM. The cumulative incidence of chronic extensive GVHD was 
74%. This rate was comparable with what was observed in patients with a variety of hematologic 
malignancies who received the same nonmyeloablative HCT conditioning.
42
 Long-term systemic 
therapy was needed to control GVHD over time, with 25% of current patients reported to still be on 
immunosuppression 7 years after allografting. In this study, we were not able to associate clinical 
GVHD with protection from relapse. However, we observed prolonged survival after relapse. Of 51 
patients who experienced relapse or progression after auto/alloHCT, the probability of survival 2 
years after relapse was 65% and 76% for the subgroup of patient who received the autologous HCT 
within 10 months from primary therapy. Attal et al reported that, with median follow-ups of 2.4 and 
2.5 years after relapse in the single and double autologous HCT group, respectively, the probability 
of survival 2 years after relapse was only 36% in both groups.
25
 It is possible that our patients 
benefited from effective salvage treatments, as other studies have reported,
43–46
 or that ongoing 
GVM effects continued to modulate disease activities.  
In summary, auto/alloHCT is a treatment option for patients with advanced stage MM, and we 
observed encouraging results, particularly in patients who received autologous HCT within 10 
months from primary therapy. Nonetheless, long-term disease control remains an issue. Results of 
large prospective studies, such as the BMT-CTN 0102 trial, are needed to evaluate the outcome of 
auto/alloHCT compared with double autologous HCT. The addition of novel agents (eg, 
thalidomide, bortezomib, and lenalidomide) as induction or postgrafting therapy, acting with GVM 
effects against disease-specific antigens, might further improve the outcome.
47–49
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